Active ingredient : Crizotinib Crizotinib
Couldn't load pickup availability
Free shipping and returns available on all orders!
We ship all US domestic orders within 5-10 business days
Xalkori, known generically as Crizotinib, is an oral medication used primarily for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). It is a targeted therapy that works by inhibiting the activity of ALK, thereby blocking the growth and spread of cancer cells.
Xalkori is indicated for the treatment of adults with:
The recommended dosage of Xalkori is 250 mg taken orally twice daily. It can be taken with or without food. Patients should swallow the capsules whole and not chew, crush, or open them.
Crizotinib is a small molecule inhibitor that selectively targets ALK and ROS1, two proteins involved in the growth of cancer cells. By inhibiting these proteins, Xalkori effectively disrupts the signaling pathways that promote tumor growth and survival.
Common side effects associated with Xalkori include:
Serious side effects may include liver problems, interstitial lung disease, and severe allergic reactions. Regular monitoring by a healthcare professional is recommended.
Xalkori may interact with various medications, including:
Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.
Store Xalkori at room temperature, away from moisture and heat. Keep it out of reach of children.
Xalkori represents a significant advancement in the targeted treatment of ALK-positive NSCLC. Patients should consult their healthcare provider for more information and to determine if Xalkori is the right treatment option for their specific condition.